{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:17:35Z","timestamp":1785421055621,"version":"3.56.0"},"reference-count":48,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universidad Anahuac Quer\u00e9taro"},{"id":[{"id":"https:\/\/ror.org\/000mgxg22","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: The EGFR T790M mutation drives lung cancer resistance by sterically hindering inhibitors and restoring ATP affinity. As C797S mutations render covalent inhibitors obsolete, novel non-covalent strategies are critical. This study identifies inhibitors that redefine the mutant methionine sulfur as a primary stabilizing anchor rather than a liability. Methods: A generative AI framework (DrugEx) sampled 100,000 molecules, prioritized via QSAR classification (ROC-AUC: 0.91 \u00b1 0.01) and Applicability Domain (AD) mapping. The workflow was de-risked through retrospective benchmarking against the DUD-E database (35,590 molecules), achieving a 1% Enrichment Factor of 5.19. Lead candidates underwent 100 ns all-atom molecular dynamics (MD) simulations. Mechanistic stability was quantified via Free Energy Landscape (FEL) analysis and ensemble-averaged MM-GBSA binding free energy calculations. Results: Candidate 106 demonstrated exceptional mutation tolerance by redistributing interactions toward the Met790 sulfur atom. MD analysis confirmed potency is dictated by successful recruitment of the thioether environment, locking the complex within a narrow thermodynamic basin. Candidate 106 maintained stable binding (\u221211.0 kcal\/mol) corroborated by an equipotent MM-GBSA \u0394Gbind of \u221250.51 kcal\/mol in the mutant system, driven by persistent \u03c0-sulfur contacts (85% occupancy). Conclusions: These results indicates that potential T790M resistance bypass is achievable by exploiting the gatekeeper methionine\u2019s electronic environment. This modeled mutation-aware framework provides a candidate non-covalent strategy to be validated in future wet-lab campaigns.<\/jats:p>","DOI":"10.3390\/pharmaceutics18070842","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:13:36Z","timestamp":1783696416000},"page":"842","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploiting the T790M Gatekeeper: A Theoretical Blueprint for Non-Covalent Inhibition of in cis Triple-Mutant EGFR"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-9191","authenticated-orcid":false,"given":"Shrikant S.","family":"Nilewar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Maliba Pharmacy College, Uka Tarsadia University, Bardoli 394350, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7782-2909","authenticated-orcid":false,"given":"Shuvadip","family":"Khanra","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Maliba Pharmacy College, Uka Tarsadia University, Bardoli 394350, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manav","family":"Pandya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Maliba Pharmacy College, Uka Tarsadia University, Bardoli 394350, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-6485","authenticated-orcid":false,"given":"Sandesh","family":"Lodha","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Maliba Pharmacy College, Uka Tarsadia University, Bardoli 394350, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1202-535X","authenticated-orcid":false,"given":"Perli Kranti","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, J.K.K. Nattraja College of Pharmacy, Kumarapalayam 638183, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2059-4849","authenticated-orcid":false,"given":"Nagaraju","family":"Bandaru","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Sree Dattha Institute of Pharmacy Sheriguda, Ibrahimpatnam, Hyderabad 501510, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Jose","family":"Naranjo-Redondo","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Ingenier\u00eda, Universidad An\u00e1huac Quer\u00e9taro, Circuito Universidades I, Fracci\u00f3n 2 S\/N, Zibat\u00e1, El Marqu\u00e9s 76246, Quer\u00e9taro, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"P\u00e9rez-Past\u00e9n-Borja","sequence":"additional","affiliation":[{"name":"Departamento de Farmacia, Escuela Nacional de Ciencias Biol\u00f3gicas, Instituto Polit\u00e9cnico Nacional, Unidad Acad\u00e9mica Adolfo L\u00f3pez Mateos, Del. GAM, Mexico City 77380, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0753-9538","authenticated-orcid":false,"given":"Tushar Janardan","family":"Pawar","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Ingenier\u00eda, Universidad An\u00e1huac Quer\u00e9taro, Circuito Universidades I, Fracci\u00f3n 2 S\/N, Zibat\u00e1, El Marqu\u00e9s 76246, Quer\u00e9taro, Mexico"},{"name":"Centro de Investigaci\u00f3n, Universidad An\u00e1huac Quer\u00e9taro, Circuito Universidades I, Fracci\u00f3n 2 S\/N, Zibat\u00e1, El Marqu\u00e9s 76246, Quer\u00e9taro, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non\u2013Small-Cell Lung Cancer to Gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or Carboplatin\u2013Paclitaxel in Pulmonary Adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and Targeting Resistance Mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired Resistance to TKIs in Solid Tumours: Learning from Lung Cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., Kris, M.G., and Varmus, H. (2005). Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020073"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR Mutation and Resistance of Non\u2013Small-Cell Lung Cancer to Gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR Inhibitor\u2013Resistant Non\u2013Small-Cell Lung Cancer","volume":"372","author":"Yang","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non\u2013Small Cell Lung Cancer Harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"ref_15","first-page":"61","article-title":"Osimertinib Acquired Resistance among Patients with EGFR-Mutated NSCLC: From Molecular Mechanisms to Clinical Therapeutic Strategies","volume":"8","author":"Wang","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17588359221144099","DOI":"10.1177\/17588359221144099","article-title":"Combatting Acquired Resistance to Osimertinib in EGFR-Mutant Lung Cancer","volume":"14","author":"Lee","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Romaniello, D., Morselli, A., and Marrocco, I. (2025). Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26072957"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","article-title":"Emerging Strategies to Overcome Resistance to Third-Generation EGFR Inhibitors","volume":"15","author":"Shi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1021\/acsmedchemlett.5c00725","article-title":"Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting","volume":"17","author":"Damghani","year":"2026","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1006\/bioo.1997.1064","article-title":"Sulfur\u2013Aromatic Interactions: A Computational Study of the Dimethyl Sulfide\u2013Benzene Complex","volume":"25","author":"Pranata","year":"1997","journal-title":"Bioorg. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"12174","DOI":"10.1039\/D3CP01146A","article-title":"Sulfur\u2013Arene Interactions: The S\u22ef\u03c0 and S\u2013H\u22ef\u03c0 Interactions in the Dimers of Benzofuran\u22efSulfur Dioxide and Benzofuran\u22efHydrogen Sulfide","volume":"25","author":"Jin","year":"2023","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm100112j","article-title":"A Medicinal Chemist\u2019s Guide to Molecular Interactions","volume":"53","author":"Bissantz","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"34979","DOI":"10.1074\/jbc.M112.374504","article-title":"The Methionine-Aromatic Motif Plays a Unique Role in Stabilizing Protein Structure","volume":"287","author":"Valley","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","article-title":"Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors for Advanced EGFR+ NSCLC","volume":"16","author":"Nagasaka","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nature03192","article-title":"Chemical Space and Biology","volume":"432","author":"Dobson","year":"2004","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41557-026-02105-w","article-title":"Expanding Diversity in Chemical Space","volume":"18","author":"Restrepo","year":"2026","journal-title":"Nat. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1021\/acs.jcim.3c00434","article-title":"DrugEx: Deep Learning Models and Tools for Exploration of Drug-Like Chemical Space","volume":"63","author":"Luukkonen","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00894-021-04674-8","article-title":"Generative Chemistry: Drug Discovery with Deep Learning Generative Models","volume":"27","author":"Bian","year":"2021","journal-title":"J. Mol. Model."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Cai, C., Lin, M., Li, W., Chen, G., and Huang, D. (2026). A Unified Multi-Scale Deep Learning Framework for Molecular Property Prediction That Bridges Molecular Structures and Fingerprinting. Commun. Chem.","DOI":"10.1038\/s42004-026-02010-w"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: Towards Direct Deposition of Bioassay Data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_33","unstructured":"Landrum, G. (2026, February 06). RDKit: Open-Source Cheminformatics Software; (Release 2023.09.1) 2016. Available online: https:\/\/github.com\/rdkit\/rdkit."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/ci100050t","article-title":"Extended-Connectivity Fingerprints","volume":"50","author":"Rogers","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random Forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach. Learn."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1021\/jm9602928","article-title":"The Properties of Known Drugs. 1. Molecular Frameworks","volume":"39","author":"Bemis","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Nilewar, S.S., Chobe, S., Dudhe, P., Kumar, P.K., Lodha, S., Raut, A.D., Fern\u00e1ndez-Conde, D., Farhan, M., Muteeb, G., and Pawar, T.J. (2026). An Integrated QSAR-MD-DCCM Pipeline: A Predictive Computational Platform for the Rational Design and Dynamic Functional Validation of Dual-Target Directed Ligands. Pharmaceuticals, 19.","DOI":"10.3390\/ph19020249"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7352","DOI":"10.1021\/acs.jcim.5c00641","article-title":"Generative Deep Learning for de Novo Drug Design\u2014A Chemical Space Odyssey","volume":"65","author":"Brinkmann","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/ci500588j","article-title":"DataWarrior: An Open-Source Program for Chemistry-Aware Data Visualization and Analysis","volume":"55","author":"Sander","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.bmc.2013.02.014","article-title":"Design and Synthesis of Novel Pyrimido [4,5-b]azepine Derivatives as HER2\/EGFR Dual Inhibitors","volume":"21","author":"Kawakita","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/elps.1150181505","article-title":"SWISS-MODEL and the Swiss-Pdb Viewer: An Environment for Comparative Protein Modeling","volume":"18","author":"Guex","year":"1997","journal-title":"Electrophoresis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1021\/ci300604z","article-title":"Lessons Learned in Empirical Scoring with Smina from the CSAR 2011 Benchmarking Exercise","volume":"53","author":"Koes","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Nilewar, S.S., Chavan, A.D., Pradhan, A.R., Tripathy, A.A., Bandaru, N., Dudhe, P.B., Kumar, P.K., Lodha, S., Muteeb, G., and Peredo-Valderrama, I. (2026). Dual-Site Acetylcholinesterase Inhibition and Multiscale Stability of Fused Quinoline Sulfonamides: A Chemoinformatic GA-MLR and Molecular Dynamics Study. Int. J. Mol. Sci., 27.","DOI":"10.20944\/preprints202603.0640.v1"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Nilewar, S.S., Chobe, S.S., Gurav, A.D., Kureshi, S.B., Palande, S.B., Escobar-Cabrera, J., Hern\u00e1ndez-Rosas, F., and Pawar, T.J. (2026). Galloylation-Driven Anchoring of the Asp325-Asp336 Ridge: The Molecular Logic Behind the Superior Kinetic Stabilization of HMPV Fusion Protein by Green Tea Dimeric Catechins. Molecules, 31.","DOI":"10.20944\/preprints202601.1028.v1"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin. Cancer Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/842\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:15:02Z","timestamp":1783696502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["pharmaceutics18070842"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18070842","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}